Physician profile
Kevin Wu
NPI 1043274228
$11,897.22
in general payments reported to CMS, 2019-2025
52 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $1,381 · 2021: $1,904 · 2022: $1,913 · 2023: $1,786 · 2024: $1,694 · 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,475 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,475.30 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.88 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,212.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,111.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,004.54 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $974.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $768.07 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $733.55 | 2019-2025 | Verquvo, Lagevrio, Belsomra |
| Pfizer INC. | $513.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $469.16 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.96 | 2019-2025 | Jardiance, Synjardy |
| Allergan, INC. | $299.91 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $279.71 | 2019-2025 | Zoryve |
| Astellas Pharma US INC | $258.41 | 2020-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $184.74 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $179.36 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.